Protara Therapeutics
TARA
120 hedge funds and large institutions have $176M invested in Protara Therapeutics in 2026 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 28 reducing their positions, and 17 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 28
64% more call options, than puts
Call options by funds: $169K | Put options by funds: $103K
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
5% more funds holding
Funds holding: 114 → 120 (+6)
2.27% less ownership
Funds ownership: 84.24% → 81.97% (-2.3%)
26% less capital invested
Capital invested by funds: $237M → $176M (-$61.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$10.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.88M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.13M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.09M |
| 5 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$8.45M |
| 2 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$5.37M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.5M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$3.43M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.87M |
TARA Hedge Fund Activity: Q2 2026 in Review
120 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2026, worth a combined $176M — down 26% from $237M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TARA positions and 17 closed out — a net gain of 9 holders — while 51 added to existing stakes and 28 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $10.6M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $8.45M sold.
- 120 institutional investors held Protara Therapeutics (TARA) as of Q2 2026, up from 114 in Q1 2026.
- Funds reported $176M of Protara Therapeutics stock for Q2 2026, down 26% quarter-over-quarter.
- 26 funds opened new Protara Therapeutics positions in Q2 2026 and 17 closed out, a net change of +9 holders.
- The largest Protara Therapeutics buyer in Q2 2026 was OrbiMed, an estimated $10.6M added.
- The largest Protara Therapeutics seller in Q2 2026 was AIGH Capital Management, an estimated $8.45M sold.
Based on aggregated 13F filings for Q2 2026.